Clear Search

Showing 1 result for “paradoxical palmoplantar pustulosis.”.

May 2023

Un patient atteint d'une pustulose palmoplantaire paradoxale réfractaire induite par l'adalimumab a été traité avec succès par l'Ixekizumab : Rapport de cas

Clin Cosmet Investig Dermatol. 2023;16:879–881 doi 10.2147/CCID.S406164

Ixekizumab, has been shown to be efficacious against paradoxical palmoplantar pustulosis which has been reported following the administration of therapeutic TNFi. Following the increased use of biologic therapies that improve patients’ quality of life are causing paradoxical adverse effects

suite…